Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about Therapy: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
Knowledge base pages for this entity
| Target | Relation | Type | Str |
|---|---|---|---|
| Lung Cancer Evolution | causes | process | 0.95 |
| Lung Cancer | treats | disease | 0.85 |
| Lung Cancer | drives | disease | 0.80 |
| Source | Relation | Type | Str |
|---|---|---|---|
| Therapeutic Resistance | suppresses | phenotype | 0.75 |
| 19654408 | is a target for | paper | 0.60 |
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
endocrinology | 2026-04-13 | 2 hypotheses Top: 0.653
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| Mobile App-Based Intervention for BPSD in Community-Dwelling Dementia | clinical | dementia with behavioral and p | 0.950 | 0.00 | human patients | proposed | N/A |
| GWAS of plasma NfL in East Asian cohort | exploratory | Alzheimer's disease | 0.950 | 0.00 | human patients - East Asian co | proposed | N/A |
| GWAS of plasma pTau217 in East Asian cohort | exploratory | Alzheimer's disease | 0.950 | 0.00 | human patients - East Asian co | proposed | N/A |
| Dairy intake and dementia risk in Malmö Diet and Cancer cohort | clinical | Alzheimer's disease | 0.950 | 0.00 | Swedish community-based adults | proposed | N/A |
| Tet2 modulation in Aβ42-injured mouse hippocampal neurons | exploratory | Alzheimer's disease | 0.900 | 0.00 | primary mouse hippocampal neur | proposed | N/A |
| GWAS of composite biomarker score | exploratory | Alzheimer's disease | 0.900 | 0.00 | human patients - East Asian co | proposed | N/A |
| RBG treatment in ApoE-/- atherosclerosis mouse model | validation | atherosclerosis | 0.900 | 0.00 | ApoE-/- mice | proposed | N/A |
| Brain Connectivity-Targeted tACS Trial in Early AD | clinical | Alzheimer's Disease | 0.509 | 0.50 | human postmortem brain tissue | proposed | $520,000 |
| Proximity labeling approach combined with proteomics identified subcel | computational | Alzheimer's disease | 0.500 | 0.00 | human | extracted | N/A |
| Single-nucleus RNA sequencing of temporal neocortex showed nominally i | gene_expression | Alzheimer's disease | 0.500 | 0.00 | in_vivo | extracted | N/A |
| iPSC-derived AD model with optical electrophysiology enabled mechanist | cell_biology | Alzheimer's disease | 0.500 | 0.00 | ipsc | extracted | N/A |
| Phosphorylated mTOR levels in spheroids correlated with AD severity in | neuropathology | Alzheimer's disease | 0.500 | 0.00 | human | extracted | N/A |
| Proximity labeling proteomics in mouse brains revealed similar spheroi | computational | Alzheimer's disease | 0.500 | 0.00 | mouse | extracted | N/A |
| Proximity labeling proteomics of axonal spheroids in human postmortem | computational | Alzheimer's disease | 0.500 | 0.00 | in_vivo | extracted | N/A |
| s:** - Test whether HCN1 knockout specifically in EC layer II accelera | falsification | Alzheimer's Disease | 0.400 | 0.50 | cell_line | proposed | $80,000 |
| AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Positive Indiv | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $6,550,000 |
| AD Combination Therapy Trial: Anti-Aβ + Anti-Tau | clinical | Alzheimer's Disease | 0.400 | 0.50 | cell_line | proposed | $180,000 |
| Biomarker-Guided Sequential Therapy Selection in Alzheimer's Disease | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| tACS Connectivity Trial in Early Alzheimer's | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Brain Connectivity-Targeted tACS Trial in Early AD | clinical | Alzheimer's Disease | 0.400 | 0.50 | mouse | proposed | $730,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Complement C1q/C3-CR3 signaling pathway mediates abnormal microglial phagocytosi [PMID:38642614] | Han QQ, Shen SY, Liang LF, Chen XR, Yu J | Brain Behav Immun | 2024 | 1 |
| An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wid [PMID:38753766] | Huang Q, Chan KY, Wu J, Botticello-Romer | Science | 2024 | 1 |
| Increased mitophagy protects cochlear hair cells from aminoglycoside-induced dam [PMID:35471096] | Zhang Y, Fang Q, Wang H, Qi J, Sun S, Li | Autophagy | 2023 | 1 |
| Metabolic orchestration of cell death by AMPK-mediated phosphorylation of RIPK1. [PMID:37384704] | Zhang T, Xu D, Trefts E, Lv M, Inuzuka H | Science | 2023 | 1 |
| ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies. [PMID:36348357] | Raulin AC, Doss SV, Trottier ZA, Ikezu T | Mol Neurodegener | 2022 | 1 |
| TREM2, microglia, and Alzheimer's disease. [PMID:33516818] | Qin Q, Teng Z, Liu C, Li Q, Yin Y, Tang | Mech Ageing Dev | 2021 | 1 |
| APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therape [PMID:33340485] | Serrano-Pozo A, Das S, Hyman BT | Lancet Neurol | 2021 | 1 |
| BNIP3L/NIX degradation leads to mitophagy deficiency in ischemic brains. [PMID:32722981] | Wu X, Zheng Y, Liu M, Li Y, Ma S, Tang W | Autophagy | 2021 | 1 |
| Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. [PMID:31564456] | Long JM, Holtzman DM | Cell | 2019 | 1 |
| Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. [PMID:31367008] | Yamazaki Y, Zhao N, Caulfield TR, Liu CC | Nat Rev Neurol | 2019 | 1 |
| The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Mic [PMID:28930663] | Krasemann S, Madore C, Cialic R, Baufeld | Immunity | 2017 | 1 |
| Complement and microglia mediate early synapse loss in Alzheimer mouse models. [PMID:27033548] | Hong S, Beja-Glasser VF, Nfonoyim BM, Fr | Science | 2016 | 1 |
| SIRT5 regulation of ammonia-induced autophagy and mitophagy. [PMID:25700560] | Polletta L, Vernucci E, Carnevale I, Arc | Autophagy | 2015 | 1 |
| PRKAB2 as a tumor suppressor in renal cell carcinoma: inhibiting mitophagy via t [PMID:41612594] | Chen K, Zhang Y, Ruan H, Wei Z, Wang K, | Autophagy | 2026 | 0 |
| Coenzyme Q10 Supplementation Modulates Hepatic Lipidomic Alterations and Attenua [PMID:41754105] | Go Y, Joung H, Han SY, Chung J | Nutrients | 2026 | 0 |
| Anatomical and neurochemical profiles of somatostatin-positive neurons in the mo [PMID:41796787] | Tomioka R, Kobayashi K, Song WJ | Neuroscience | 2026 | 0 |
| Subtype-Specific Roles of Anterior Cingulate Cortex Neurons in Pain-Induced Soci [PMID:41799202] | Wan X, Yan Z, Zhang Z, Liu X, Yang D, Zh | Theranostics | 2026 | 0 |
| ROS-responsive nanogels for brain targeted delivery of icariin in the treatment [PMID:41197818] | ["Li X", "Huang J", "Zhou Y", "Chen X", | International journal of pharm | 2026 | 0 |
| Single-Cell RNA Sequencing and Network Pharmacology Reveal the Potential Role of [PMID:41610872] | ["Niu J", "Wang L", "Qi J", "Lu G"] | The journal of gene medicine | 2026 | 0 |
| CRISPR-based correction of apolipoprotein E4 in Alzheimer's disease: Therapeutic [PMID:41812941] | ["Wang M", "Niu D", "Zhang Q", "Tang Y", | International journal of biolo | 2026 | 0 |
Multi-agent debates referencing this entity
Hypotheses and analyses mentioning Therapy in their description or question text
Score: 0.782 · neurodegeneration · 2026-04-02
## Mechanistic Overview Selective Acid Sphingomyelinase Modulation Therapy starts from the claim that modulating SMPD1 w
Score: 0.768 · neurodegeneration · 2026-04-02
## Mechanistic Overview CYP46A1 Overexpression Gene Therapy starts from the claim that modulating CYP46A1 within the dis
Score: 0.758 · neurodegeneration · 2026-04-02
**Molecular Mechanism and Rationale** The apolipoprotein E4 (APOE4) variant represents the most significant genetic ris
Score: 0.742 · neurodegeneration · 2026-04-02
## Mechanistic Overview Near-infrared light therapy stimulates COX4-dependent mitochondrial motility enhancement starts
Score: 0.742 · neurodegeneration · 2026-04-02
## Mechanistic Overview APOE4-Selective Lipid Nanoemulsion Therapy starts from the claim that modulating APOE within the
Score: 0.738 · neurodegeneration · 2026-04-02
## Mechanistic Overview PARP1 Inhibition Therapy starts from the claim that modulating PARP1 within the disease context
Score: 0.731 · neurodegeneration · 2026-04-12
**Molecular Mechanism and Rationale** The pathophysiological foundation of this therapeutic approach centers on the dys
Score: 0.718 · neurodegeneration · 2026-04-02
## Mechanistic Overview APOE Isoform Conversion Therapy starts from the claim that modulating APOE within the disease co
Score: 0.712 · neurodegeneration · 2026-04-02
## Mechanistic Overview Circadian Glymphatic Rescue Therapy (Melatonin-focused) starts from the claim that modulating MT
Score: 0.712 · neurodegeneration · 2026-04-04
## Molecular Mechanism and Rationale The 26S proteasome represents the primary degradation machinery for misfolded and
Score: 0.707 · neurodegeneration · 2026-04-02
## Mechanistic Overview Orexin-Microglia Modulation Therapy starts from the claim that modulating HCRTR2 within the dise
Score: 0.706 · neurodegeneration · 2026-04-02
## Mechanistic Overview TET2-Mediated Demethylation Rejuvenation Therapy starts from the claim that modulating TET2 with
Score: 0.703 · neurodegeneration · 2026-04-02
## Mechanistic Overview Purinergic P2Y12 Inverse Agonist Therapy starts from the claim that modulating P2RY12 within the
Score: 0.700 · neurodegeneration · 2026-04-25
Therapeutic benefit from pericyte-directed senescence interventions depends on stage. If BBB leak and dysfunction occur